Biotest Pharmaceuticals Corp. (BPC), a wholly owned U.S. subsidiary of Biotest AG, has entered into a strategic long-term manufacturing, supply, and license agreement with ADMA Biologics, Inc. (ADMA).
ADMA has agreed to purchase its worldwide requirements of RSV (Respiratory Syncytial Virus) Immune Globulin manufactured from human plasma, exclusively from BPC. The initial term of the agreement is for ten years. BPC will receive payment for manufacturing services as well as specified royalties on ADMA's product sales. In exchange, BPC granted ADMA a license to use its fractionation and purification manufacturing process for Intravenous Immune Globulin.
"We are very pleased to partner with ADMA on their lead product candidate. Our ability to provide specialized contract manufacturing services will enable us to diversify our future revenue sources," said Jordan Siegel, chief executive officer of BPC.